Mar. Drugs 2013, 11(7), 2293-2313; doi:10.3390/md11072293
Strategies for the Development of Conotoxins as New Therapeutic Leads
Monash Institute of Pharmaceutical Science, Monash University, 381 Royal Parade, Parkville 3052, Australia
*
Author to whom correspondence should be addressed.
Received: 14 April 2013 / Revised: 27 May 2013 / Accepted: 6 June 2013 / Published: 28 June 2013
(This article belongs to the Special Issue Marine Peptides and Their Mimetics)
Abstract
Peptide toxins typically bind to their target ion channels or receptors with high potency and selectivity, making them attractive leads for therapeutic development. In some cases the native peptide as it is found in the venom from which it originates can be used directly, but in many instances it is desirable to truncate and/or stabilize the peptide to improve its therapeutic properties. A complementary strategy is to display the key residues that make up the pharmacophore of the peptide toxin on a non-peptidic scaffold, thereby creating a peptidomimetic. This review exemplifies these approaches with peptide toxins from marine organisms, with a particular focus on conotoxins. View Full-TextKeywords:
peptide toxin; peptidomimetic; ion channel; pain; cone snail
▼
Figures
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Scifeed alert for new publications
Never miss any articles matching your research from any publisher- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Share & Cite This Article
MDPI and ACS Style
Brady, R.M.; Baell, J.B.; Norton, R.S. Strategies for the Development of Conotoxins as New Therapeutic Leads. Mar. Drugs 2013, 11, 2293-2313.
Related Articles
Article Metrics
Comments
[Return to top]
Mar. Drugs
EISSN 1660-3397
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert